Nebulgen Bambini (Flunisolide)

Flunisolide, the active ingredient in Nebulgen Bambini, is a corticosteroid presented as a nebulized solution for inhalation use. It reduces airway inflammation and hyper‑responsiveness, providing relief in asthma and, off‑label, chronic obstructive pulmonary disease for both children and adults.

GNH USA supplies Nebulgen Bambini as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, transplant centres and clinics worldwide, ensuring quality‑controlled batches and reliable logistics for global markets. All shipments meet EU GMP standards and are accompanied by full documentation.

Flunisolide is an inhaled corticosteroid that acts on the inflammatory pathway of respiratory diseases.

Asthma: reduces airway inflammation and improves symptom control. Chronic obstructive pulmonary disease (off‑label): helps decrease exacerbations and improves lung function. Allergic airway disease: mitigates bronchial inflammation associated with allergic triggers.

Flunisolide may cause a range of adverse reactions.

Common Side Effects: - Throat irritation or soreness. - Hoarseness or dysphonia. - Cough during or after inhalation. - Oral candidiasis (thrush). - Headache.

Serious or Rare Side Effects: - Adrenal suppression with prolonged high‑dose use. - Growth retardation in pediatric patients. - Severe allergic reactions such as anaphylaxis. - Pneumonia or other opportunistic infections. - Paradoxical bronchospasm.

Use Nebulgen Bambini with careful clinical monitoring.

Dose adjustment: employ the lowest effective dose to limit systemic exposure. Monitor growth: pediatric patients should have regular height and weight assessments. Avoid abrupt discontinuation: taper the dose after long‑term therapy to prevent adrenal insufficiency. Use mouth rinse: rinse the mouth after inhalation to reduce risk of oral candidiasis. Pregnancy and lactation: evaluate risk‑benefit with the prescriber as safety data are limited. Store at ambient temperature: keep below 25°C, protect from moisture and light in the original container.

Flunisolide can interact with other medicines; some require avoidance while others need monitoring.

Major Interactions (Avoid): - Systemic CYP3A4 inhibitors (e.g., ketoconazole) may raise systemic corticosteroid levels. - Strong immunosuppressants (e.g., azathioprine) increase risk of infection. - Live vaccines: heightened risk of vaccine‑derived infection.

Moderate Interactions (Monitor Closely): - Azole antifungals: may modestly increase exposure. - Ritonavir or other protease inhibitors: can elevate plasma concentrations. - Short‑acting β2‑agonists: may mask worsening asthma symptoms.